Protein-Core Spherical Nucleic Acids for Targeted Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for cancer face challenges in delivering antigens and adjuvants safely and effectively, often leading to non-specific immune responses and excess inflammation, and struggle to target the appropriate immune cells for cancer treatment.
Innovation Solution
The development of immunostimulatory protein-core spherical nucleic acids (SNAs) with a protein core and a shell of oligonucleotides, where the ratio of immunostimulatory to non-immunostimulatory oligonucleotides can be adjusted to stimulate specific T-cell responses, such as CD4+ or CD8+ T-cell activation, by attaching oligonucleotides to the protein core via linkers, enhancing immune stimulation and reducing the need for high doses of adjuvants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional immunotherapy approaches use separate delivery of antigen and adjuvant, then the immune response can be activated, but the delivery is not safe and efficacious and leads to non-specific immune responses and excess inflammation
Solution Approach 1:
The patent combines the antigen (protein core) and adjuvant (oligonucleotide shell) into a single integrated SNA construct, allowing co-delivery to immune cells. This merging ensures both components reach their target simultaneously, improving safety and efficacy while reducing non-specific responses compared to separate delivery methods.
Solution Approach 2:
The SNA construct acts as an intermediary carrier that presents both the antigen and adjuvant in a controlled manner to immune cells. The spherical structure with surface-conjugated oligonucleotides serves as a mediator that facilitates specific immune activation while controlling the release and interaction of components.
2Reliability
If high doses of adjuvant oligonucleotides are used to achieve robust immune response, then T-cell or B-cell activation is enhanced, but adverse immune responses increase
Solution Approach 1:
The patent applies local quality by concentrating the adjuvant oligonucleotides specifically on the surface of the protein core at controlled densities. This localized arrangement ensures high immunostimulatory activity at the site of immune cell interaction while using lower overall doses of adjuvant compared to bulk administration methods, thereby reducing adverse effects.
Solution Approach 2:
The patent utilizes parameter changes by adjusting the ratio and density of adjuvant to non-specific oligonucleotides on the SNA surface. By optimizing these parameters, the system achieves robust immune responses at lower adjuvant doses, shifting the dose-response relationship to improve efficacy while minimizing harm.
3Reliability
If the surface density of oligonucleotides is increased to strengthen immune stimulation, then the immune response is enhanced, but the amount of active components must remain constant
Solution Approach 1:
The patent applies local quality by concentrating oligonucleotides at specific locations on the protein core surface. This spatial arrangement increases the local density and immunostimulatory activity without requiring proportional increases in the total amount of oligonucleotide material, thereby enhancing immune response while controlling component quantity.
Solution Approach 2:
The patent uses composite materials by creating a hybrid structure combining protein core and oligonucleotide shell. This composite architecture allows the oligonucleotides to be distributed in a controlled manner across the protein surface, achieving high surface density with optimized total material content that balances immune stimulation strength and component quantity.
Data Source
AI summary
The disclosure is generally directed to immunostimulatory protein-core spherical nucleic acids (SNAs) comprising a protein core and a ratio of immunostimulatory and non-immunostimulatory strands, methods of making the immunostimulatory protein-core SNAs as well as their use.